Professor Lewis Nelson, M.D., is available to discuss the dangers of gargling, snorting, or ingesting Betadine, an iodine-based antiseptic to treat COVID-19. “Although many topical disinfectants such as povidone-iodine, which, is also known as Betadine, generally destroy viruses on direct…
Tag: COVID-19 treatment
Medicine that treats gout could also battle COVID-19
New research from the University of Georgia offers hope for a viable therapeutic to combat the disease that has claimed more than 4 million lives worldwide.
Molecular Mechanism for COVID-19 Mortality Identified
An enzyme with an elusive role in severe inflammation may be a key mechanism driving COVID-19 severity and could provide a new therapeutic target to reduce COVID-19 mortality. This finding by a team of researchers is detailed in a study to be published in the Journal of Clinical Investigation.
Mouse Model of COVID-19–induced Lung Injury May Aid Development of Coronavirus Treatments
Article title: The SARS-CoV-2 spike protein subunit 1 induces COVID-19–like acute lung injury in Κ18-hACE2 transgenic mice and barrier dysfunction in human endothelial cells Authors: Ruben Colunga Biancatelli, Pavel Solopov, Elizabeth R. Sharlow, John S. Lazo, Paul Ellis Marik, John…
Chula Innovations for Society to Fight COVID-19
Chulalongkorn University has taken a bold step in commutating its transformation to an innovation-centric university with its “Innovations for Society” campaign. The campaign uses a short movie to inform the public about the various innovations that Chula has successfully developed to fight the COVID-19 pandemic, as part of Chula’s mission to play a leading role in “Creating Knowledge and Innovation to Promote Sustainable Development for Society”.
Tricking the novel coronavirus with a fake “handshake”
Fool the novel coronavirus once and it can’t cause infection of cells, new research suggests. Scientists have developed protein fragments that bind to the Spike protein, effectively tricking the virus into “shaking hands” with a replica rather than the receptor that lets the virus into a cell.
Keck Medicine of USC is enrolling individuals in a phase 3 clinical trial to test monoclonal antibody treatment for COVID-19
Keck Medicine of USC is enrolling individuals in a phase 3 clinical trial to test monoclonal antibody treatment for COVID-19
Preclinical testing of inhaled monoclonal antibody for COVID-19 shows therapeutic efficacy
An inhaled monoclonal antibody treatment against the SARS-CoV-2 virus may lead to self-administered therapy for COVID-19, according to preclinical tests. It was discovered at UAB and the Texas Biomedical Research Institute, and it has been licensed for development to Aridis Pharmaceuticals.
UC Davis Health tests monoclonal antibodies as potential COVID-19 treatment
Timothy Albertson has received a BARDA grant to lead a new clinical trial at UC Davis Health. The trial evaluates the efficacy, safety and tolerability of an antibody cocktail in hospitalized adult patients with COVID-19.
Evelo Biosciences, Rutgers University, and Robert Wood Johnson University Hospital Announce Submission of IND for a Phase 2 Study of EDP1815 in COVID-19 Patients
Evelo Biosciences, Inc. (Nasdaq:EVLO), Rutgers University, and Robert Wood Johnson University Hospital today announced the submission of an Investigational New Drug (IND) application for an Evelo-sponsored Phase 2 clinical study evaluating the safety and efficacy of EDP1815 for the treatment of hospitalized patients with newly diagnosed COVID-19. The study will be led by Reynold A. Panettieri, Jr., M.D., Vice Chancellor for Translational Medicine and Science at Rutgers Biomedical and Health Sciences and Professor of Medicine at Rutgers Robert Wood Johnson Medical School.
Rutgers Expert Available to Speak About the Ethics Behind Developing a COVID-19 Treatment and Vaccine
During public heath emergencies – like the COVID-19 pandemic – when no known preventive or effective treatment exists, researchers want to quickly start conducting studies with humans to find a vaccine and therapeutic treatments that are safe and effective, prompting…
Rutgers Expert Available to Speak About COVID-19 and Heightened Risk for Those Living with HIV
Preliminary data has shown that people living with HIV may be at heightened risk for severe complications from COVID-19 because they are simultaneously experiencing two epidemics that are synergistically interacting to create increased odds of death and disability. However, HIV…
Two Major COVID-19 Clinical Trials Launched to Determine Effectiveness and Safety of Drugs in Treating Coronavirus
Researchers from Intermountain Healthcare and University of Utah Health in Salt Lake City have launched two vital clinical trials to test the effectiveness and safety of two drugs – hydroxychloroquine (HCQ) and azithromycin – to treat patients with COVID-19.
Immunizing with plasma to combat COVID-19
Canada institutions are pooling their scientific expertise to develop an extraordinary immunization program using passive plasma to fight COVID-19.
Repurposing Existing Drugs Could Offer Faster Path to COVID-19 Treatment
A map of interactions between the novel coronavirus and human proteins is helping scientists identify drugs that might work as therapeutics.
Rush Testing Remdesivir as a Potential Treatment for COVID-19
Rush University Medical Center is participating in a new clinical trial to test the effectiveness of the drug remdesivir in the treatment of coronavirus disease 2019 (COVID-19).
Houston Methodist Ramps up Plasma Therapy as FDA Approves Clinical Trial
The FDA’s announcement Friday to approve convalescent serum therapy as a large-scale clinical trial opened the door for more patients to receive the potentially life-saving gift of a donor’s plasma.
Rutgers Cancer Institute Offers Clinical Trial Examining Potential Treatment for COVID-19
Rutgers Cancer Institute of New Jersey, a National Cancer Institute-designated Comprehensive Cancer Center, is offering a clinical trial as a potential treatment for patients diagnosed with the coronavirus (COVID-19). The trial, which is not limited to cancer patients is exploring hydroxychloroquine and azithromycin.
FDA Approves First Plasma Therapy for Houston Methodist COVID-19 Patient
Houston Methodist received FDA approval Saturday to become the first academic medical center in the nation to transfuse donated plasma from a recovered COVID-19 patient into a critically ill patient. This treatment was fast-tracked to the bedside over the weekend as the death toll in the COVID-19 pandemic soared to more than 2,000 people across the United States, with more than 100,000 Americans sick from the virus.